Gonadotropin-releasing hormone analogs: Understanding advantages and limitations

Pratap Kumar, Alok Sharma, Pratap Kumar, Alok Sharma

Abstract

Pituitary stimulation with pulsatile gonadotropin-releasing hormone (GnRH) analogs induces both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Pituitary gonadotropin secretions are blocked upon desensitization when a continuous GnRH stimulus is provided by means of an agonist or when the pituitary receptors are occupied with a competitive antagonist. GnRH antagonists were not available originally; therefore, prolonged daily injections of agonist with its desensitizing effect were used. Today, single- and multiple-dose injectable antagonists are also available to block the LH surge and thus to cause desensitization. This review provides an overview of the use of GnRH analogs which is potent therapeutic agents that are considerably useful in a variety of clinical indications from the past to the future with some limitations. These indications include management of endometriosis, uterine leiomyomas, hirsutism, dysfunctional uterine bleeding, premenstrual syndrome, assisted reproduction, and some hormone-dependent tumours, other than ovulation induction.

Keywords: Advantages; gonadotropin-releasing hormone analog; limitations.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Markussis V, Goni MH, Tolis G. Therapeutic use of gonadotropin-releasing hormone agonists in polycystic ovarian syndrome. Ann N Y Acad Sci. 1993;687:242–9.
    1. Fraser HM, Lunn SF, Morris KD, Deghenghi R. Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge. Hum Reprod. 1997;12:430–5.
    1. Pellicer A, Simón C, Miró F, Castellví RM, Ruiz A, Ruiz M, et al. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle. Hum Reprod. 1989;4:285–9.
    1. Daya S. The Cochrane Library. Issue 1. Oxford: Update Software; 2000. Gonadotrophin. releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gameteintrafallopian transfer cycles (Cochrane Review)
    1. San Roman GA, Surrey ES, Judd HL, Kerin JF. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril. 1992;58:744–9.
    1. Chang SY, Lee CL, Wang ML, Hu ML, Lai YM, Chang MY, et al. No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist. Fertil Steril. 1993;59:183–6.
    1. Tan SL, Brinsden P. The use of luteinising hormone releasing hormone agonists for ovarian stimulation in assisted reproductive technology. Ann Acad Med Singapore. 1992;21:504–9.
    1. Tan SL. Luteinizing hormone-releasing hormone agonists for ovarian stimulation in assisted reproduction. Curr Opin Obstet Gynecol. 1994;6:166–72.
    1. Schats R, Schoemaker J, Gardner D. 4th ed. Kamini Rao: Jaypee Publishers; 2012. The use of GnRH agonists. Textbook of ART-Lab and Clinical Perspectives.
    1. Filicori M, Flamigni C, Cognigni GE, Falbo A, Arnone R, Capelli M, et al. Different gonadotropin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis. Fertil Steril. 1996;65:387–93.
    1. Kahraman K, Berker B, Atabekoglu CS, Sonmezer M, Cetinkaya E, Aytac R, et al. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Fertil Steril. 2009;91:2437–44.
    1. Pantos K, Meimeth-Damianaki T, Vaxevanoglou T, Kapetanakis E. Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program. Fertil Steril. 1994;61:709–13.
    1. Ron-El R, Herman A, Golan A, Soffer Y, Nachum H, Caspi E. Ultrashort gonadotropin-releasing hormone agonist (GnRH-a) protocol in comparison with the long-acting GnRH-a protocol and menotropin alone. Fertil Steril. 1992;58:1164–8.
    1. Olivennes F, Fanchin R, Bouchard P, Taïeb J, Selva J, Frydman R. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: A pilot study. Hum Reprod. 1995;10:1382–6.
    1. Ludwig M, Katalinic A, Banz C, Schröder AK, Löning M, Weiss JM, et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: Results of a prospective, randomized study. Hum Reprod. 2002;17:2842–5.
    1. Manasco PK, Pescovitz OH, Feuillan PP, Hench KD, Barnes KM, Jones J, et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab. 1988;67:368–72.
    1. Goodpasture JC, Kisei L, Rosenfield R. GnRH agonists in the treatment of true precocious puberty. Infertil Reprod Med Clin North Am. 1993;4:147–70.
    1. Geisthoevel F, Hils K, Wieacker P, Breckwoldt M, Schultheiss H. Monthly administration of the LH-RH analogue decapeptyl for long-term treatment of ovarian dysfunctions and estrogen-dependent disorders. Int J Fertil. 1989;34:262–70.
    1. Parnes HL, Eisenberger M. Use of GnRH agonists in the treatment of prostate and breast cancer. Infertil Reprod Med Clin North Am. 1993;4:171–88.
    1. Emons G, Ormann O, Schutz KD. In GnRH analogues in ovarian, breast and endometrial cancer. In: Lunenfeld EB, Insler V, editors. GnRH Analogues: The State of Art 1996. New York: Parthenon Publishing; 1996. pp. 95–120.
    1. Azziz R, Ochoa TM, Bradley EL, Jr, Potter HD, Boots LR. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: A prospective randomized study. J Clin Endocrinol Metab. 1995;80:3406–11.
    1. Sutton CJ, Ewen SP. Thinning the endometrium prior to ablation: Is it worthwhile? Br J Obstet Gynaecol. 1994;101(Suppl 10):10–2.
    1. Mortola JF. Use of GnRH agonists in premenstrual syndrome. Infertil Reprod Med Clin North Am. 1993;4:51–64.
    1. Chen H, Li J, Cui T. Adjuvant gonadotropin releasing hormone analogues for chemotherapy induced premature ovarian in premenopausal women. Cochrane Rev. 2011;11:CD008018.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi